FDA Soundcast: KYMRIAH, first CAR-T cell immunotherapy
KYMRIAH, CAR-T cell immunotherapy- an entirely new treatment approach for patients with cancer FDA Approvals: KYMRIAH, MYLOTARG, VABOMERE, Benznidazole
- Produced by taking patient’s blood sample, isolating T lymphocytes, and genetically engineering those T-cells to express a new chimeric receptor that recognizes CD19 on their leukemia and normal B-cells
- Engineered T-cell should recognize and kill B-cells, including the malignant cells
Image credit: FDA